Foaming behaviour of primary, secondary and tertiary aqueous solution of amine for the removal of carbon dioxide

This study is focusing on the effect by the usage of different amine in order to remove acid gases that is foaming. Foam is made up of thousands of gas filled bubbles. Bubbles are formed when a liquid film encapsulates gas. This research is to investigate the foaming behaviour on the different cases for the primary (monoethanolamine, MEA), secondary (diethanolamine, DEA) and tertiary (methyldiethanolamine, MDEA) amine on the effect of concentration, temperature and impurities. Effect of all this parameters will be evaluated based on height of foam and collapse time of foam. Nitrogen gas (N2) will be used in this experiments as bubble gas. For this work several hypothesis has been set according to respectively cases. The hypothesis of this study is a higher solution concentration of MEA will reduce the foaminess. Other hypothesis is a higher solution temperature of MEA and DEA will reduce the foaminess also. Effects of impurities toward foaming formation are classified as following: iron sulphide, for MDEA solution foaming decrease; sodium chloride, for MDEA solution tendency for formation of foam decrease; methanol, foaming decrease in MDEA solution. It is apparently iron sulphide meet the most influential contaminants to the foam formation at the same concentrations of all impurities studie

Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis acrossphase III and long‐term extension studies

Objective: The risk of cardiovascular disease (CVD) is higher in patients with psoriatic arthritis (PsA) compared to the general population. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Because tofacitinib increases circulating lipid levels in some patients, we evaluated CVD risk factors and major adverse cardiovascular events (MACE) in patients with active PsA receiving tofacitinib 5 or 10 mg twice daily plus conventional synthetic disease‐modifying antirheumatic drugs. Methods: Data were pooled from 2 phase III studies (Efficacy and Safety of Tofacitinib in Psoriatic Arthritis [OPAL Broaden] and Tofacitinib in Patients with Psoriatic Arthritis With Inadequate Response to TNF Inhibitors [OPAL Beyond]) and 1 ongoing long‐term extension (Open‐Label Extension Study of Tofacitinib in Psoriatic Arthritis [OPAL Balance], data cutoff January 2017; database not locked). Outcomes included fasting lipid levels, blood pressure, hypertension‐related adverse events (AEs; including hypertension, high blood pressure, and increased blood pressure), and MACE. Results: Overall, 783 tofacitinib‐treated patients were included. Percentage increases from baseline in low‐density lipoprotein cholesterol (LDL‐c) and high‐density lipoprotein cholesterol (HDL‐c) levels ranged from 9% to 14% for tofacitinib 5 mg and 10 mg at 3 and 6 months; no meaningful changes in LDL‐c:HDL‐c or total cholesterol:HDL‐c ratios were observed. Blood pressure remained stable for 24 months. Fifty‐eight patients (7.4%) had hypertension‐related AEs; none were fatal (incidence rate [IR] per 100 patient‐years 4.81 [95% confidence interval (95% CI) 3.65–6.22]). Five patients (0.6%) had MACE (IR 0.24 [95% CI 0.05–0.70]); 2 were fatal. Conclusion: Serum lipid level increases at month 3 following tofacitinib treatment in PsA were consistent with observations in rheumatoid arthritis and psoriasis. The IR of hypertension‐related AEs and MACE was low; long‐term follow‐up is ongoing

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

Objective: To describe the efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) in a post-hoc analysis of randomised controlled trials. Methods: Data were collected from patients in seven tofacitinib studies: six phase III (four RA, two PsA) and one phase II study (AS), and grouped into five analysis populations based on rheumatic disease diagnosis and category of prior inadequate response (IR) to treatment: conventional synthetic disease-modifying antirheumatic drugs-IR (RA and PsA), tumour necrosis factor inhibitors-IR (RA and PsA), or non-steroidal anti-inflammatory drugs-IR (AS). Only patients who received tofacitinib 5 or 10 mg twice daily or placebo were included. Pain assessments included: Patient’s Assessment of Arthritis Pain, Short-Form Health Survey 36v2 Question (Q)7 and Bodily Pain domain, Ankylosing Spondylitis Quality of Life Q9 and Q14, EuroQol Five Dimensions Pain/Discomfort dimension and Bath Ankylosing Spondylitis Disease Activity Index Q2 and Q3. Data were reported to month 6 (placebo to month 3) in the RA and PsA populations, and week 12 (tofacitinib and placebo) in the AS population. Results: Overall, 3330 patients were included in this analysis. In the RA and PsA populations, pain improvements in tofacitinib-treated patients compared with placebo were observed at the earliest time point assessed and at month 3 (maintained to month 6). In the AS population, pain improvements compared with placebo were observed at week 12. Conclusion: Tofacitinib was associated with rapid and sustained improvements across multiple pain measures in patients with inflammatory rheumatic musculoskeletal diseases

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

Objectives: Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). We evaluated patient-reported outcomes (PROs) in patients with PsA refractory to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and tumour necrosis factor inhibitor-naïve in a 12-month, phase III randomised controlled trial (OPAL Broaden [NCT01877668]). Methods: Patients (N=422) received tofacitinib 5 mg or 10 mg twice daily, adalimumab 40 mg subcutaneously every 2 weeks or placebo advancing to tofacitinib 5 mg or 10 mg twice daily at month 3. Least squares mean changes from baseline and percentages of patients reporting improvements ≥minimum clinically important differences (MCID); and scores ≥normative values in: Patient Global Assessment of disease activity (PtGA), Pain, Patient Global Joint and Skin Assessment (PGJS), Short Form-36 Health Survey version 2 (SF-36v2), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), EuroQol 5-Dimensions-3-level questionnaire (EQ-5D-3L) and Ankylosing Spondylitis Quality of Life (ASQoL) were determined. Nominal p values were cited without multiple comparison adjustments. Results: At month 3, PtGA, Pain, PGJS, FACIT-Fatigue, EQ-5D-3L, ASQoL and SF-36v2 Physical Component Summary (PCS), physical functioning (PF), bodily pain (BP) and vitality domain scores exceeded placebo with both tofacitinib doses (p≤0.05); SF-36v2 social functioning with 5 mg twice daily (p≤0.05). Percentages reporting improvements ≥MCID in PtGA, Pain, PGJS, FACIT-Fatigue, ASQoL and SF-36v2 PCS, PF, BP and general health scores exceeded placebo with both tofacitinib doses (p≤0.05) and were similar with adalimumab. Conclusion: csDMARD-IR patients with active PsA reported statistically and clinically meaningful improvements in PROs with tofacitinib compared with placebo at Month 3

Fully Automatic Segmentation and Three-Dimensional Reconstruction of the Liver in CT Images

Automatic segmentation and three-dimensional reconstruction of the liver is important for liver disease diagnosis and surgical treatment. However, the shape of the imaged 2D liver in each CT image changes dramatically across the slices. In all slices, the imaged 2D liver is connected with other organs, and the connected organs also vary across the slices. In many slices, the intensities of the connected organs are the same with that of the liver. All these facts make automatic segmentation of the liver in the CT image an extremely difficult task. In this paper, we propose a heuristic approach to segment the liver automatically based on multiple thresholds. The thresholds are computed based on the slope difference distribution that has been proposed and verified in the previous research. Different organs in the CT image are segmented with the automatically computed thresholds, respectively. Then, different segmentation results are combined to delineate the boundary of the liver robustly. After the boundaries of the 2D liver in all the slices are identified, they are combined to form the 3D shape of the liver with a global energy minimization function. Experimental results verified the effectiveness of all the proposed image processing algorithms in automatic and robust segmentation of the liver in CT images

Fractional-order Sliding Mode Control of Hybrid Drive Wind Turbine for Improving Low-voltage Ride-through Capacity

A hybrid drive wind turbine equipped with a speed regulating differential mechanism can generate electricity at the grid frequency by an electrically excited synchronous generator without requiring fully or partially rated converters. This mechanism has extensively been studied in recent years. To enhance the transient operation performance and low-voltage ride-through capacity of the proposed hybrid drive wind turbine, we aim to synthesize an advanced control scheme for the flexible regulation of synchronous generator excitation based on fractional-order sliding mode theory. Moreover, an extended state observer is constructed to cooperate with the designed controller and jointly compensate for parametric uncertainties and external disturbances. A dedicated simulation model of a 1.5 MW hybrid drive wind turbine is established and verified through an experimental platform. The results show satisfactory model performance with the maximum and average speed errors of 1.67% and 1.05%, respectively. Moreover, comparative case studies are carried out considering parametric uncertainties and different wind conditions and grid faults, by which the superiority of the proposed controller for improving system on-grid operation performance is verified

Microstructure and Wear Resistance of Laser-Clad (Co, Ni)61.2B26.2Si7.8Ta4.8 Coatings

It has been reported that a quaternary Co61.2B26.2Si7.8Ta4.8 alloy is a good glass former and can be laser-clad to an amorphous composite coating with superior hardness and wear resistance. In this paper, alloys with varying Ni contents to substitute for Co are coated on the surface of #45 carbon steel using a 5-kW CO2 laser source for the purpose of obtaining protective coatings. In contrast to the quaternary case, the clad layers are characterized by a matrix of α-(Fe, Co, Ni) solid solution plus CoB, Co3B, and Co3Ta types of precipitates. The cladding layer is divided into four regions: Near-surface dendrites, α-(Fe, Co, Ni) solid solution plus dispersed particles in the middle zone, columnar bonding zone, and heat-affected area that consists of martensite. The hardness gradually decreases with increasing Ni content, and the maximum hardness occurs in the middle zone. Both the friction coefficient and wear volume are minimized in the alloy containing 12.2% Ni. Compared with the previous cobalt-based quaternary alloy Co61.2B26.2Si7.8Ta4.8, the addition of the Ni element reduces the glass-forming ability and henceforth the hardness and wear resistance of the clad layers

Real-time online monitoring technology for sweeping frequency ultrasound (SFU) assisted extraction of amur grape (Vitis amurensis) seed oil

Sweeping frequency ultrasound (SFU) was used to assist extraction of amur grape (Vitis amurensis) seed (AGS) oil. Extraction conditions and physicochemical properties were optimized and analyzed under different extraction methods. Meanwhile, frequency and time domains were online monitored during SFU assisted extraction of AGS oil. PVDF piezoelectric sensor was used in time domain, and the hydrophone in frequency domain, so as to obtain the time–voltage waveform, signal power, spectrum distribution and other visual models. Physical models of the spatial peak acoustic intensity, charge quantity and work done by electric field force under different ultrasonic conditions were derived. The mathematical model between the work done by electric field force and the spatial peak acoustic intensity under the working state of PVDF piezoelectric sensor was constructed. Results show that the content of AGS oil by SFU assisted extraction was higher than that by organic extraction. Furthermore, the optimal single-frequency was 40 kHz and dual-frequency was 28/33 kHz, and SFU extraction time of 30 min was suitable with higher oil yield of 16.70 % and 16.94 %, respectively. In addition, the selection and combination of SFU also affected the oil oxidation degree. The peak voltage, spatial peak acoustic intensity, signal power and work of electric field force at 28/33 kHz were all higher than those at 40 kHz

Month 2 Culture Status and Treatment Duration as Predictors of Tuberculosis Relapse Risk in a Meta-Regression Model

<div><p>Background</p><p>New drugs and regimens with the potential to transform tuberculosis treatment are presently in early stage clinical trials.</p><p>Objective</p><p>The goal of the present study was to infer the required duration of these treatments.</p><p>Method</p><p>A meta-regression model was developed to predict relapse risk using treatment duration and month 2 sputum culture positive rate as predictors, based on published historical data from 24 studies describing 58 regimens in 7793 patients. Regimens in which rifampin was administered for the first 2 months but not subsequently were excluded. The model treated study as a random effect.</p><p>Results</p><p>The model predicted that new regimens of 4 or 5 months duration with rates of culture positivity after 2 months of 1% or 3%, would yield relapse rates of 4.0% or 4.1%, respectively. In both cases, the upper limit of the 2-sided 80% prediction interval for relapse for a hypothetical trial with 680 subjects per arm was <10%. Analysis using this model of published month 2 data for moxifloxacin-containing regimens indicated they would result in relapse rates similar to standard therapy only if administered for ≥5 months.</p><p>Conclusions</p><p>This model is proposed to inform the required duration of treatment of new TB regimens, potentially hastening their accelerated approval by several years.</p></div